DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/m955fm/recurrent_malignan) has announced the addition of Global Markets Direct's new report "Recurrent Malignant Glioma - Pipeline Review, H2 2012" to their offering.
Recurrent Malignant Glioma - Pipeline Review, H2 2012
Summary:
Global Markets Direct's, 'Recurrent Malignant Glioma - Pipeline Review, H2 2012', provides an overview of the Recurrent Malignant Glioma therapeutic pipeline. This report provides information on the therapeutic development for Recurrent Malignant Glioma, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Recurrent Malignant Glioma. 'Recurrent Malignant Glioma - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Key Topics Covered:
List of Tables of Figures 6
Introduction 7
REPORT COVERAGE 7
Recurrent Malignant Glioma Overview 8
Therapeutics Development 9
An Overview of Pipeline Products for Recurrent Malignant Glioma 9
Recurrent Malignant Glioma Therapeutics under Development by Companies 11
Recurrent Malignant Glioma Therapeutics under Investigation by Universities/Institutes 12
Mid Clinical Stage Products 14
Comparative Analysis 14
Early Clinical Stage Products 15
Comparative Analysis 15
Recurrent Malignant Glioma Therapeutics - Products under Development by Companies 16
Recurrent Malignant Glioma Therapeutics - Products under Investigation by Universities/Institutes 17
Companies Involved in Recurrent Malignant Glioma Therapeutics Development 18
Boehringer Ingelheim GmbH 18
Eli Lilly and Company 19
Genentech, Inc. 20
Merck & Co., Inc. 21
Oncolytics Biotech Inc. 22
BioNumerik Pharmaceuticals, Inc. 23
Stemline Therapeutics, Inc. 24
Recurrent Malignant Glioma - Therapeutics Assessment 25
Assessment by Monotherapy Products 25
Assessment by Combination Products 26
Assessment by Route of Administration 27
Assessment by Molecule Type 29
Drug Profiles 31
Recurrent Malignant Glioma Therapeutics - Drug Profile Updates 70
Recurrent Malignant Glioma Therapeutics - Discontinued Products 78
Recurrent Malignant Glioma Therapeutics - Dormant Products 79
Appendix 80
For more information visit http://www.researchandmarkets.com/research/m955fm/recurrent_malignan
Source: Global Markets Direct